Dulaglutide vs. Exenatide as Add-On Therapy in T2DM Trial
the MPR take:
In a new 52-week study published in the journal Diabetes Care, researchers aimed to find out whether adding dulaglutide, a once-weekly GLP-1 receptor agonist, to a diabetes treatment regimen that includes pioglitazone and metformin would improve HbA1c in type 2 diabetes patients. In this trial, patients were randomized to receive dulaglutide 1.5mg, dulaglutide 0.75mg, exenatide 10mcg, or placebo. Study results showed that both doses of dulaglutide were superior to exenatide (at 26 and 52 weeks) and placebo (at 26 weeks). HbA1c targets were reached by a greater percentage of patients taking dulaglutide 0.75mg and 1.5mg than exenatide or placebo. Researchers concluded that both dulaglutide 0.75mg and 1.5mg once-weekly showed superior glycemic control versus exenatide and placebo in patients with type 2 diabetes.
OBJECTIVE: To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. RESEARCH DESIGN AND METHODS: This 52-week, multicenter, parallel-arm study (primary end point: 26 weeks) randomized patients (2:2:2:1) to dulaglutide 1.5mg, dulaglutide 0.75mg, exenatide 10g, or placebo (placebo-controlled period: 26 weeks).
READ FULL ARTICLE From Diabetesjournals